Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Michael C. Heinrich, Jean Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Robin L. Jones, Yoon‐Koo Kang, Albiruni R. Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Kjetil Boye, David Goldstein, César Sánchez, Brittany L. Siontis, P. H. Cox, Erika Davis, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Sebastian Bauer (2025). Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE. , 43(20), DOI: https://doi.org/10.1200/jco-24-02818.
Article19 days agoINSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.
Michael C. Heinrich, Jean Yves Blay, Ping Chi, Robin L. Jones, César Serrano, Neeta Somaiah, Hans Gelderblom, John Zalcberg, William M. Reichmann, Kam Sprott, Matthew L. Sherman, Sebastian Bauer, Suzanne George (2025). INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.. , 43(4_suppl), DOI: https://doi.org/10.1200/jco.2025.43.4_suppl.tps848.
Article19 days agoOverall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.
John Zalcberg, Robin L. Jones, Jean Yves Blay, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Erika Davis, Haroun Achour, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Sebastian Bauer, Michael C. Heinrich (2024). Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.. , 42(3_suppl), DOI: https://doi.org/10.1200/jco.2024.42.3_suppl.748.
Article19 days ago62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutations: ctDNA analysis from INTRIGUE
Jean Yves Blay, Robin L. Jones, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Y-K. Kang, A.R. Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Emily Davis, Kam Sprott, P. H. Cox, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich, Sebastian Bauer (2024). 62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutations: ctDNA analysis from INTRIGUE. , 9, DOI: https://doi.org/10.1016/j.esmoop.2024.102452.
Article19 days agoINSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.
John Zalcberg, Jean Yves Blay, Ping Chi, Robin L. Jones, César Serrano, Neeta Somaiah, William M. Reichmann, Kam Sprott, P. H. Cox, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich, Sebastian Bauer, Suzanne George (2024). INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.. , 42(3_suppl), DOI: https://doi.org/10.1200/jco.2024.42.3_suppl.tps767.
Article19 days ago